Aug. 19 at 6:30 PM
$HUMA HUMA’s V007 Phase 3 results are not new, but their publication in the peer-reviewed Lancet Digital Health gives them independent scientific validation rather than relying solely on company-reported data. This strengthens the credibility of ATEV’s superiority in high-risk dialysis patients and, together with the positive V012 Phase 3 results, supports HUMA’s upcoming dialysis sBLA. That matters because dialysis is a much larger commercial opportunity than trauma and could fundamentally change HUMA’s value if approved.
